Thus, MDAMB231 breast cancer cells were treated with another microtubule disruptor (nocodazole), a MEK inhibitor (PD98059), the metabolic inhibitors BPTES and 968 (which allosterically block the activation of the mitochondrial enzyme glutaminase), various DNA synthesis inhibitors (doxorubicin, fluorouracil, etoposide, and cisplatin), receptor tyrosine kinase inhibitors (Gefitinib and AG538), an inhibitor of actin polymerization (cytochalasin D), and a heat shock protein (HSP)90 inhibitor (17-AAG). The gene discussed is MAP2K7; the disease is breast cancer.